Table 2.
Summary of post-surgery radiotherapy and hormonal therapy (intent-to-treat population)
| CT-P6 (N = 271) | Trastuzumab (N = 278) | |
|---|---|---|
| Patients with surgery, n (%) | 258 (95.2) | 261 (93.9) |
| Patients with ≥ 1 RT, n (%) | 142 (55.0) | 131 (50.2) |
| Breast only | 60 (23.3) | 60 (23.0) |
| Breast + axilla only | 7 (2.7) | 15 (5.7) |
| Breast + SCV/IMC/other ± axilla | 57 (22.1) | 48 (18.4) |
| Breast + other ± axilla | 13 (5.0) | 9 (3.4) |
| Breast + axilla + SCV ± other | 26 (10.1) | 20 (7.7) |
| Breast + axilla + SCV + IMC ± other | 3 (1.2) | 3 (1.1) |
| Breast + SCV + IMC ± other | 1 (0.4) | 2 (0.8) |
| Othera | 18 (7.0) | 8 (3.1) |
| Patients with ≥ 1 hormonal therapy, n (%) | 102 (39.5) | 99 (37.9) |
| Anastrozole | 23 (8.9) | 20 (7.7) |
| Exemestane | 0 | 2 (0.8) |
| Letrozole | 17 (6.6) | 20 (7.7) |
| Tamoxifenb | 63 (24.4) | 55 (21.1) |
| Toremifene | 2 (0.8) | 1 (0.4) |
| Goserelinb | 14 (5.4) | 9 (3.4) |
| Leuprorelin acetate | 1 (0.4) | 1 (0.4) |
The denominator for percentage was the number of patients who had breast surgery during the neoadjuvant period in the ITT population
IMC internal mammary chain, ITT intent-to-treat, PPS per-protocol set, RT radiotherapy, SCV supraclavicular
aAll other region combinations not shown in the preceding list
bTwo patients in the CT-P6 treatment group who initiated hormonal treatment were excluded from the PPS as these were considered to be major protocol deviations